A new clinical program will use ibogaine, a naturally occurring psychedelic, to treat neurodegenerative conditions including Parkinson’s disease.

Ambio Life Sciences, which hosts other ibogaine programming and participates in scientific research about the drug, soft-launched the program in February. It is the first of its kind in the world, according to the company. People with Parkinson’s,